Insightz

Home  Insightz
U.S. Job Market Update: June Shows Hiring Slowdown Amid Concentrated Growth in Healthcare and Government

U.S. Job Market Update: June Shows Hiring Slowdown Amid Concentrated Growth in Healthcare and Government

The U.S. job market showed signs of slowing in June 2025, with employers adding 147,000 jobs and the unemployment rate edging down to 4.1%. However, job growth remains highly concentrated in the healthcare, social assistance,…

U.S. Stock Market Hits Record Highs in July 2025 Amid Strong Tech Earnings and Fed Watch

U.S. Stock Market Hits Record Highs in July 2025 Amid Strong Tech Earnings and Fed Watch

The U.S. stock market reached record highs in July 2025, driven by robust technology sector earnings and investor focus on Federal Reserve policy decisions. Strong quarterly reports from leading tech companies boosted market confidence, while…

Blackstone Mourns Tragic Shooting at Manhattan Headquarters: Honoring Wesley LePatner’s Legacy and Lives Lost

Blackstone Mourns Tragic Shooting at Manhattan Headquarters: Honoring Wesley LePatner’s Legacy and Lives Lost

Blackstone mourns the tragic loss of Wesley LePatner, an executive killed during the devastating mass shooting at its Manhattan headquarters on July 28, 2025. The attack at 345 Park Avenue, which also targeted NFL offices…

U.S. Stock Futures Rise Ahead of Key Tech Earnings and Federal Reserve Meeting This Week

U.S. Stock Futures Rise Ahead of Key Tech Earnings and Federal Reserve Meeting This Week

U.S. stock futures are rising ahead of highly anticipated tech earnings reports and the upcoming Federal Reserve meeting this week. Investors are closely watching major technology companies for signs of growth while assessing potential impacts…

FDA Allows Sarepta to Resume Shipping Elevidys Gene Therapy for Duchenne Muscular Dystrophy with Safety Restrictions

FDA Allows Sarepta to Resume Shipping Elevidys Gene Therapy for Duchenne Muscular Dystrophy with Safety Restrictions

FDA has authorized Sarepta Therapeutics to resume shipping ELEVIDYS, a groundbreaking gene therapy for Duchenne muscular dystrophy (DMD), with new safety restrictions in place. ELEVIDYS is a one-time intravenous gene therapy designed to treat both…

Mid-2025 Market and Economic Insights: Key Trends and What Investors Need to Know

Mid-2025 Market and Economic Insights: Key Trends and What Investors Need to Know

Discover the latest mid-2025 market and economic insights to stay ahead in investing. This article highlights key trends shaping the global economy and essential strategies investors need to know for informed decision-making. Stay updated with…

Is Robinhood a Smart Buy in 2025? A Deep Dive into Its User Growth and Financial Surge

Is Robinhood a Smart Buy in 2025? A Deep Dive into Its User Growth and Financial Surge

Robinhood is showing strong growth potential in 2025, driven by impressive user expansion and robust financial performance. With funded customers reaching 25.5 million and assets under custody nearly doubling year-over-year to $204 billion, the platform…

Trump Administration Intensifies Criminal Enforcement Against Tariff Evasion: What Importers and Corporations Must Know

Trump Administration Intensifies Criminal Enforcement Against Tariff Evasion: What Importers and Corporations Must Know

The Trump administration has significantly intensified criminal enforcement against tariff evasion, signaling a new era of strict scrutiny for importers and corporations. With a major reorganization within the Department of Justice’s Criminal Division and increased…

1 53 54 55 56 57 91

1uptick Analytics @

Maximize your profit at ease

Risk Warning​

*Investment involves risk. You may use the information, strategies and trading signals on this website for academic and reference purposes at your own discretion. 1uptick cannot and does not guarantee that any current or future buy or sell comments and messages posted on this website/app will be profitable. Past performance is not necessarily indicative of future performance. It is impossible for 1uptick to make such guarantees and users should not make such assumptions. Readers should seek independent professional advice before executing a transaction. 1uptick will not solicit any subscribers or visitors to execute any transactions, and you are responsible for all executed transactions.

© 2022-25 – 1uptick Analytics all rights reserved.

 
 
Risk Warning​

*Investment involves risk. You may use the information, strategies and trading signals on this website for academic and reference purposes at your own discretion. 1uptick cannot and does not guarantee that any current or future buy or sell comments and messages posted on this website/app will be profitable. Past performance is not necessarily indicative of future performance. It is impossible for 1uptick to make such guarantees and users should not make such assumptions. Readers should seek independent professional advice before executing a transaction. 1uptick will not solicit any subscribers or visitors to execute any transactions, and you are responsible for all executed transactions.

© 1uptick Analytics all rights reserved.

Home
Analysis
Calendar
Tools
Signals